Incyte Corp

Insider Clancy Paul J buys 15,000 Incyte shares at $84.53, reinforcing executive optimism on AI‑driven growth and signaling a buy‑or‑hold for investors.

Insider buying by Incyte’s CMO signals confidence in its late‑stage pipeline and suggests a potential rally for investors.

Insider buying at Incyte signals confidence in its oncology pipeline – see why Cagnoni’s trades suggest a bullish outlook.

Trotta Matteo’s 537‑share sale shows routine liquidity, not a warning: insider buys and new leadership signal Incyte’s growing confidence and future upside.

Heeson Lee’s small February sale of Incyte shares shows disciplined insider trading amid the company’s steady growth and solid oncology pipeline.

Incyte insider sale: EVP Issa Khairie’s January 2026 tax‑related share sale shows routine trading, not a confidence dip, amid strong oncology pipeline growth.

Incyte insider sale by EVP Steven H. Stein shows disciplined portfolio moves, not a warning, amid Monjuvi success and strong growth prospects.